For the quarter ended June 2025, Aspen Aerogels (ASPN) reported revenue of $78.02 million, down 33.8% over the same period last year. EPS came in at -$0.04, compared to $0.21 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $72.07 million, representing a surprise of +8.26%. The company delivered an EPS surprise of +66.67%, with the consensus EPS estimate being -$0.12.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Aspen Aerogels performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:View all Key Company Metrics for Aspen Aerogels here>>>
Shares of Aspen Aerogels have returned +8.1% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| Oct-22 | |
| Sep-18 | |
| Aug-06 | |
| Aug-06 | |
| Aug-06 | |
| Aug-05 | |
| Aug-04 | |
| Jul-23 | |
| Jun-03 | |
| May-14 | |
| May-07 | |
| May-07 | |
| May-06 | |
| Apr-23 | |
| Apr-21 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite